MBX Biosciences, a clinical-stage biopharmaceutical company, announced that its CEO Kent Hawryluk and CMO Dr. Sam Azoulay will present at the Jefferies 2026 Global Healthcare Conference in New York City on June 3, 2026. The presentation will cover the company's progress in developing novel precision peptide therapies for endocrine and metabolic disorders, including updates on their obesity portfolio and Phase 3 trial preparations for canvuparatide. This event provides an opportunity for investors to learn about MBX Biosciences' pipeline advancements and upcoming clinical milestones. The webcast will be available live and replayed on the company’s website.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
